Contact information
adan.pintofernandez@ndm.ox.ac.uk
CAMS Oxford Institute, Old Road Campus, University of Oxford
Adán Pinto-Fernández
Career Development Fellow at Chinese Academy of Medical Sciences Oxford Institute
TRANSLATIONAL STUDIES OF THE UBIQUITIN SYSTEM - CANCER IMMUNOLOGY
Current research involves the study of the roles of a class of druggable enzymes called deubiquitylating enzymes (DUBs) in cancer inflammation using advanced proteomics, lipidomics, and immunology techniques as main tools.
For instance, we have recently discovered that cancer cells lacking the DUB USP18, a negative regulator of the interferon pathway, are more antigenic and radiosensitive. At a molecular level, USP18-deficient cells accumulate innate immune ligands such as dsRNA, enhance the antigen presentation machinery, and hence they can activate more efficiently cytotoxic T cells, resulting in enhanced T cell killing and immunotherapy responses. Read more here.
Recent publications
Altered Hormone and Bioactive Lipid Plasma Profile in Rodent Models of Polycystic Ovarian Syndrome Revealed by Targeted Mass Spectrometry
Journal article
Scott HC. et al, (2025), Journal of Endocrinology and Metabolism, 15, 1 - 14
Identification of a new Plasmodium falciparum E2 ubiquitin conjugating enzyme
Preprint
Smith C. et al, (2024)
USP24 is an ISG15 cross-reactive deubiquitinase that mediates IFN-I production by de-ISGylating the RNA helicase MOV10
Preprint
Mukhopadhyay R. et al, (2024)
Deubiquitinases in muscle physiology and disorders.
Journal article
Olie CS. et al, (2024), Biochem Soc Trans, 52, 1085 - 1098
Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1.
Journal article
Imhoff RD. et al, (2024), J Med Chem, 67, 4496 - 4524